BACKGROUND: We set out in this study to demonstrate the adverse effect profile of methotrexate when used in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in a district general hospital population, and to investigate the effect of alcohol consumption in these patients. METHODS: A prospective evaluation of 550 RA patients and 69 PsA patients was undertaken, controlling for confounding factors. Systematically randomised patients were further analysed regarding alcohol consumption. A transaminase level of three times the upper limit of normal on two or more occasions was taken to indicate hepatic injury. RESULTS: Gastrointestinal disturbance was the predominant adverse effect in RA patients (9.8%); hepatic disturbance was the most frequent in PsA patients (14.5%). Both groups had hepatic enzyme elevation; PsA patients were at significantly greater risk of elevated transaminases than RA patients (14.5% vs 7.5%, respectively, chi2 = 4.017). Alcohol consumption did not correlate with hepatic injury (mean 5.15 vs 6.6 alcohol units/week consumed by RA and PsA patients, respectively). CONCLUSION: Our data show methotrexate-treated PsA patients have a higher incidence of hepatotoxicity compared with methotrexate-treated patients with RA. It is proposed that psoriatic patients may be inherently more susceptible to methotrexate hepatotoxicity than are rheumatoid patients.
BACKGROUND: We set out in this study to demonstrate the adverse effect profile of methotrexate when used in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in a district general hospital population, and to investigate the effect of alcohol consumption in these patients. METHODS: A prospective evaluation of 550 RApatients and 69 PsA patients was undertaken, controlling for confounding factors. Systematically randomised patients were further analysed regarding alcohol consumption. A transaminase level of three times the upper limit of normal on two or more occasions was taken to indicate hepatic injury. RESULTS: Gastrointestinal disturbance was the predominant adverse effect in RApatients (9.8%); hepatic disturbance was the most frequent in PsA patients (14.5%). Both groups had hepatic enzyme elevation; PsA patients were at significantly greater risk of elevated transaminases than RApatients (14.5% vs 7.5%, respectively, chi2 = 4.017). Alcohol consumption did not correlate with hepatic injury (mean 5.15 vs 6.6 alcohol units/week consumed by RA and PsA patients, respectively). CONCLUSION: Our data show methotrexate-treated PsA patients have a higher incidence of hepatotoxicity compared with methotrexate-treated patients with RA. It is proposed that psoriaticpatients may be inherently more susceptible to methotrexatehepatotoxicity than are rheumatoidpatients.
Authors: M E Weinblatt; H Kaplan; B F Germain; R C Merriman; S D Solomon; B Wall; L Anderson; S Block; R Irby; F Wolfe Journal: Arthritis Rheum Date: 1990-03
Authors: Y Ohosone; Y Okano; H Kameda; N Hama; M Matsumura; T Nojima; K Nakamura; M Kuwana; T Ogasawara; M Hirakata; T Yoshida; T Mimori; M Akizuki; Y Ikeda Journal: Ryumachi Date: 1997-02
Authors: L R Espinoza; L Zakraoui; C G Espinoza; F Gutiérrez; L J Jara; L H Silveira; M L Cuéllar; P Martínez-Osuna Journal: J Rheumatol Date: 1992-06 Impact factor: 4.666
Authors: M E Weinblatt; H Kaplan; B F Germain; S Block; S D Solomon; R C Merriman; F Wolfe; B Wall; L Anderson; E Gall Journal: Arthritis Rheum Date: 1994-10
Authors: Martin Feuchtenberger; Lisa Kraus; Axel Nigg; Hendrik Schulze-Koops; Arne Schäfer Journal: Rheumatol Int Date: 2021-02-20 Impact factor: 2.631
Authors: K Visser; W Katchamart; E Loza; J A Martinez-Lopez; C Salliot; J Trudeau; C Bombardier; L Carmona; D van der Heijde; J W J Bijlsma; D T Boumpas; H Canhao; C J Edwards; V Hamuryudan; T K Kvien; B F Leeb; E M Martín-Mola; H Mielants; U Müller-Ladner; G Murphy; M Østergaard; I A Pereira; C Ramos-Remus; G Valentini; J Zochling; M Dougados Journal: Ann Rheum Dis Date: 2008-11-25 Impact factor: 19.103